Cachexia is a significant loss of muscle and adipose tissue. It occurs in patients with advanced cancer, chronic obstructive pulmonary disease, chronic infection including AIDS and tuberculosis, chronic heart failure, and rheumatoid arthritis. Increases in pro-inflammatory factors characterize cachexia. There is a decreased quality of life, decreased tolerance to surgical or medical interventions, and shortened survival.
Cachexia is not simple starvation where fat stores replace glucose as the primary fuel. Cancer causes a change in metabolism as opposed to an energy deficit, so conventional nutritional support is not effective.
Cancer-related cachexia can be broken down into 3 categories:
The causes of cachexia can be related to the disease, treatment, or emotional distress. Nausea, early satiety, and dysgeusia are factors in anorexia.
Mediators of cachexia associated with cancer include tumor necrosis factor-alpha, interleukins (IL) 1 and 6, ciliary neurotrophic factor, and leukemia inhibitory factor, and interferon (INF)-gamma. These produced by tumor cells and host immune cells. These are procachectic factors, as they lead to anorexia, weight loss, protein, and fat breakdown, an acute-phase protein response, falls in insulin level, insulin resistance, rises in levels of cortisol and glucagon, fever, anemia, and elevated energy expenditure.
Host immune cells including macrophages, T-helper-one cells, and myeloid-derived suppressor cells produce procachectic cytokines.
Many tumors cause an elevated adrenergic state that results in an increased rate of energy expenditure. Skeletal muscle is the primary s as part of a persistent inflammatory response. Tumors only produce proteolysis-inducing (PIF) factor. Tumor necrosis factor (TNF)-alpha and PIF induce cachexia by activating nuclear factor kappa B transcription factor found in muscles.ite of lean body mass depletion. This is secondary to increased protein turnover without equivalent protein synthesis.
The JAK/STAT3 pathway is strongly activated by the IL-6 family ligands. STAT3 activation by IL-6 is necessary for muscle wasting. Inhibition STAT3 pharmacologically using STAT3 or JAK inhibitors reduce muscle atrophy. This indicates that STAT3 is a primary mediator of muscle wasting when there is high IL-6 family signaling.
Anorexia and weight loss in cancer patients do not correlate with serum levels of circulating IL-1, IL-6, IFN-gamma, and TNF-alpha. There may be a central mechanism of action producing of cachexia. Cytokines postulated to be involved include TNF-alpha, IFN-alpha, IL-1, IL-6, IL-8, and others.
Serotonin and dysfunction of neuropeptidergic circuits may be involved. Elevated plasma-free tryptophan was observed in patients with cancer and anorexia. This elevates tryptophan levels in the cerebrospinal fluid resulting in increased synthesis of serotonin. Elevated levels of serotonin contribute to cancer anorexia.
Insulin and Ghrelin
Insulin and leptin levels are proportional to body fat content. Central nervous system (CNS) concentrations are proportional to plasma levels. Insulin secretion increases as weight increase. This occurs at the basal state and in response to meals. Leptin is more involved in CNS control of energy homeostasis than insulin. Leptin deficiency causes obesity with hyperphagia. This persists despite high insulin levels.
Ghrelin function is a peptide produced by ghrelin cells in the gastrointestinal (GI) tract and acts in the CNS. Ghrelin is secreted when the stomach is empty. Secretion stops when the stomach is stretched. Ghrelin acts centrally to increase hunger, gastric acid, secretion, and gastrointestinal motility. The same brain cells have receptors for ghrelin and leptin, with opposing effects.
Alimentary Tract Dysfunction
Cancer patients often have abnormalities in their taste and smell. Oral intake may be impaired by tumors of the mouth, neck, esophagus, stomach. Obstruction can occur to tumors of the pancreas, liver, and peritoneum. Intestinal obstruction is common. Enzymatic insufficiency secondary to pancreatic insufficiency may contribute to malabsorption. Lymphoma of the intestine or mesentery can result in issues.
Slowing of peristalsis and delayed gastric emptying contributes to early satiety. Chemotherapy commonly causes nausea vomiting, mucositis, and abnormal perception of taste. Stomatitis, alterations in taste and smell, and xerostomia often occur secondary to radiotherapy to the head and neck. Abdominal radiation therapy can cause nausea, vomiting, anorexia, diarrhea, and malabsorption.
Biochemical and Metabolic Derangement
Neoplastic cells have high levels of glucose utilization and production of lactic acid, the Warburg effect. Hexokinase is the first step of the glycolytic pathway and overexpressed in tumor cells contributes to this process. Tumor glycolysis and host gluconeogenesis may be an important cause of cancer cachexia.
Recently, an extensive re-examination of Warburg effects shows that unlike the majority of cells, numerous cancer cell lines obtain a significant portion of their energy from aerobic glycolysis. Many malignant cells secrete hydrogen peroxide, oxygen free radicals drives mitophagy, aerobic glycolysis, and autophagy.
Theorized Causes of Cancer Anorexia
Orexigenic and Anorexigenic Neuropeptides
The cachexia prevalence ranges from 5% to 15% in congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD) to 60% to 80% in advanced cancer. Mortality rates of patients COPD and cachexia are 10% to 15% per year. In patients with cachexia and CHF or chronic kidney, disease mortality is 20% to 30% per year, and it is 80% in patients in cachectic cancer patients.
The multiple signaling pathways that cause muscle atrophy are interdependent. Inhibition or activation or inhibition of a single pathway often causes a cascade affecting muscle protein balance.
Reactive Oxygen Species and Oxidative Stress
Cancer cachexia results in metabolic reprogramming of muscle and adipose tissues. Fatty acids are catabolized by cancer cells to provide energy for tumor growth. Invasion of adipose tissue by cancer cells induces the release of free fatty acids from adjacent adipocytes. Autophagy and lysosomal degradation result in muscle wasting. HSL and ATGL knockdown studies reveal that they mediate muscle degradation.
There is selective parasitism by the tumor of the host. There is competition for substrates with tumors acting as nitrogen traps independent of protein intake. Given that the total tumor mass in most patients is usually less than 550 g and that patients with very small tumors can have cachexia, it is doubtful that simple competition for nitrogen is responsible for cachexia.
The definition of cancer cachexia includes weight loss of more than 5% over 12 months, BMI of less than 20, or sarcopenia as evidenced by dual-energy x-ray absorptiometry.
Stages of Cancer Cachexia
Intervention from the stage of pre-cachexia is best. Early nutritional intervention can improve nutritional status. This may reduce the inflammatory response. Stabilization of body weight during chemotherapy often results in reduced toxicity and longer overall survival. The following have all shown limited success.
Exercise is safe during active cancer treatments. It improves muscle strength, bone health, and quality of life, while decreasing depression, fatigue, and psychosocial distress. Physical activity can reduce the risk of comorbidities negatively affecting cancer survivors. There is evidence indicating that exercise is associated with a reduction in overall mortality. Physical exercise can improve insulin sensitivity, modulate muscle metabolism, and reduce the inflammation. Exercise has anti-inflammatory benefits. It up-regulates anti-inflammatory cytokines in skeletal muscle and adipose tissue. Recommendations should be made for exercise early in the treatment of cancer. Physical therapy evaluation can be helpful. Caregiver participation improves compliance.
Multiple agents with different mechanisms of action can be used alone or in combination.
Olanzapine, a selective monoaminergic antagonist, has a strong affinity for dopamine and serotonin receptors. It has been used at low doses showing improvement in weight and nutritional status with a low incidence of side effects.
Ghrelin and its analogs, including anamorelin have been shown to be effective. Side effects included nausea and hyperglycemia.
Recombinant-human GH with insulin has been evaluated and showed improved whole-body protein net balance.
Anabolic androgenic steroids have been used to promote muscle growth and strength. Nandrolone decanoate was studied in patients with non-small cell lung cancer. The treated group had less weight loss, but survival was comparable. Fluoxymesterone, an anabolic steroid, was found to be inferior to megestrol acetate or dexamethasone.
Enobosarm (GTx-024) is an androgen receptor modulator. It has tissue-selective anabolic effects in muscle and bone. One study showed an increase in lean body mass.
Thalidomide suppresses TNF production in patients with cancer. It has been used in combination with medroxyprogesterone or megestrol acetate, oral eicosapentaenoic acid, and L-carnitine resulting a significant increase in lean body mass significantly, decreased fatigue, and improved appetite.
MABp1 (Xilonix; Xbiotech, Inc., Austin, TX) is a fully humanized, monoclonal anti-IL-1a antibody. It is a receptor antagonist that resulted in partial remission or stabilization of cachexia.
Corticosteroids have been found in uncontrolled studies to diminish anorexia, asthenia, and pain in patients with cancer. The improvements did not persist, and all nutritional status returned to baseline with no differences in mortality rate.
Megestrol acetate has been used historically. It improves appetite and increases body fat more than lean body mass. There is a reduction of serum levels of IL-1a and b, IL-2, IL-6, and TNF-a.
Medroxyprogesterone acetate is a synthetic progestagen that also has been used. It reduces production of cytokines and serotonin. It has been to increase appetite but not weight.
Metoclopramide can be used for patients with delayed gastric emptying or gastroparesis.
Dronabinol and Marijuana Dronabinol (Delta 9-tetrahydrocannabinol, THC) have been studied. Cannabinoids have not shown to be more effective than megestrol despite improved appetite.
The anti-tnf antibody has been studied with conflicting results.
Eicosapentaenoic acid was found to have antitumor and anti-cachexia activities in animal cachexia models, but randomized clinical studies show no unique benefit of EPA.
Myostatin inhibitors may be a new potential therapeutic target. Activin type-2 receptor (ActRIIB) has been used to treat of muscle wasting. ActRIIB is a high-affinity activin type 2 receptor that is known to mediate the signaling via a subset of TGF-b family ligands including myostatin, activin, GDF11, and others.
Bimagrumab is a fully humanized anti-ActRII monoclonal antibody that is to be studied for non-small cell lung cancer associated cachexia.
NSAIDs including indomethacin and celecoxib have not been shown to improve nutritional status.
Hydrazine sulfate is an inhibitor of the enzyme phosphoenolpyruvate carboxykinase. It interrupts gluconeogenesis in animals. Studies have shown no benefit.
Beta-hydroxy-beta-methyl butyrate with L-arginine and L-glutamine has been used for cachexia. HMB is a metabolite of leucine and interferes with the activation of NF-kB. In tumor-bearing mice, it inhibited PIF-induced protein degradation and attenuated the increased protein degradation.
OHR/AVR118 (OHR Pharmaceuticals, Inc., New York, NY) is a broad-spectrum peptide-nucleic acid immunomodulator is theorized to have cytoprotective properties. A study in patients with cancer showed stabilization of body mass and muscle mass, increased appetite, and enhanced quality of life.
Total parenteral nutrition (TPN) has not been shown to have significant benefit for patients undergoing chemotherapy or radiation therapy regarding tolerance, response, or survival.
Cancer cachexia is a well-known problem for many patients with advanced malignancy. The cause of the cachexia is multifactorial and is best managed by an interprofessional team that consists of an oncologist, oncology nurse, dietitian, social worker, pharmacist, physical therapist, and a mental health counselor. The key is to recognize the problem early, when treatment is most successful. Even though there are many pharmacological agents that may help boost appetite, long-term studies on the effectiveness of these agents are lacking. At a minimum, the patient should be seen by a dietitian and a therapist. Improving the mood and offering supportive services may also help. Sadly, when cancer cachexia is advanced the outlook for most patients is poor and thus one should always try and ensure that the quality of life does not deteriorate.
The oncology nurse should focus their attention on monitoring the patient and making sure regular followup appointments are maintained. Family education by the nurse is important. If the patient has signs of cachexia, the nurse should report their concerns to the clinician managing the case. The pharmacist also plays a role, oftentimes the pharmacist can provide additional pharmaceutical solutions that may help manage the patient. Further, with the complexity of the combination of medical therapy, reconciliation of the medications is important and reporting to the clinician if there is a concern of medication combinations that may be making the condition worse. While extremely challenging, the best outcomes will be achieved by an interprofessional team providing care. [Level V]
|||Del Fabbro E, Combination therapy in cachexia. Annals of palliative medicine. 2018 Aug 27 [PubMed PMID: 30180745]|
|||Turcott JG,Oñate-Ocaña LF,Soca-Chafre G,Ramírez-Tirado LA,Flores-Estrada D,Zatarain-Barrón ZL,Arrieta O, FAACT-Anorexia Cachexia Scale: Cutoff Value for Anorexia Diagnosis in Advanced Non-Small Cell Lung Cancer Patients. Nutrition and cancer. 2018 Oct 1 [PubMed PMID: 30273069]|
|||Hopkinson J, Psychosocial Support in Cancer Cachexia Syndrome: The Evidence for Supported Self-Management of Eating Problems during Radiotherapy or Chemotherapy Treatment. Asia-Pacific journal of oncology nursing. 2018 Oct-Dec [PubMed PMID: 30271817]|
|||Li F,Ruan X,Min L, Targeting both sides of the GDF15-GFRAL-RET receptor complex: A new approach to achieve body weight homeostasis. Genes [PubMed PMID: 30258922]|
|||Tsai VWW,Husaini Y,Sainsbury A,Brown DA,Breit SN, The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases. Cell metabolism. 2018 Sep 4 [PubMed PMID: 30184485]|
|||Zhang F,Shen A,Jin Y,Qiang W, The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews. BMC complementary and alternative medicine. 2018 Aug 9 [PubMed PMID: 30092794]|
|||Rassy EE,Ghosn M,Rassy NA,Assi T,Robert C, Do immune checkpoint inhibitors perform identically in patients with weight extremes? Immunotherapy. 2018 Jul [PubMed PMID: 30008261]|
|||Arrieta O,Luvián-Morales J,Turcott JG,Oñate-Ocaña LF, Quality of life and anorexia/cachexia in lung cancer: validation of the Spanish version of the FAACT instrument. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2018 Jul 10 [PubMed PMID: 29987501]|
|||Barajas Galindo DE,Vidal-Casariego A,Calleja-Fernández A,Hernández-Moreno A,Pintor de la Maza B,Pedraza-Lorenzo M,Rodríguez-García MA,Ávila-Turcios DM,Alejo-Ramos M,Villar-Taibo R,Urioste-Fondo A,Cano-Rodríguez I,Ballesteros-Pomar MD, Appetite disorders in cancer patients: Impact on nutritional status and quality of life. Appetite. 2017 Jul 1 [PubMed PMID: 28315777]|
|||Castillo-Martínez L,Castro-Eguiluz D,Copca-Mendoza ET,Pérez-Camargo DA,Reyes-Torres CA,Ávila EA,López-Córdova G,Fuentes-Hernández MR,Cetina-Pérez L,Milke-García MDP, Nutritional Assessment Tools for the Identification of Malnutrition and Nutritional Risk Associated with Cancer Treatment. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. 2018 [PubMed PMID: 29943772]|
|||Serpe R,Demurtas L,Puzzoni M,Madeddu C,Scartozzi M, [Cancer cachexia assessment: new tools for oncologists.] Recenti progressi in medicina. 2016 Oct [PubMed PMID: 27782227]|
|||Hagmann C,Cramer A,Kestenbaum A,Durazo C,Downey A,Russell M,Geluz J,Ma JD,Roeland EJ, Evidence-based Palliative Care Approaches to Non-pain Physical Symptom Management in Cancer Patients. Seminars in oncology nursing. 2018 Aug [PubMed PMID: 30120000]|
|||Mattox TW, Cancer Cachexia: Cause, Diagnosis, and Treatment. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition. 2017 Oct [PubMed PMID: 28825869]|
|||Arends J,Baracos V,Bertz H,Bozzetti F,Calder PC,Deutz NEP,Erickson N,Laviano A,Lisanti MP,Lobo DN,McMillan DC,Muscaritoli M,Ockenga J,Pirlich M,Strasser F,de van der Schueren M,Van Gossum A,Vaupel P,Weimann A, ESPEN expert group recommendations for action against cancer-related malnutrition. Clinical nutrition (Edinburgh, Scotland). 2017 Oct [PubMed PMID: 28689670]|
|||Watanabe D,Horiguchi A,Tasaki S,Kuroda K,Sato A,Asakuma J,Ito K,Asano T, Impact of body mass index on clinicopathological outcomes in patients with renal cell carcinoma without anorexia-cachexia syndrome. Molecular and clinical oncology. 2018 Jan [PubMed PMID: 29387396]|
|||Garcia JM, What is next after anamorelin? Current opinion in supportive and palliative care. 2017 Dec [PubMed PMID: 28957883]|